Automated analysis of a novel anti-epileptic compound, CGP 33,101, and its metabolite, CGP 47,292, in body fluids by high-performance liquid chromatography and liquid-solid extraction.
Automated procedures for the determination of CGP 33,101 in plasma and the simultaneous determination of CGP 33,101 and its carboxylic acid metabolite, CGP 47,292, in urine are described. Plasma was diluted with water and urine with a pH 2 buffer prior to extraction. The compounds were automatically extracted on reversed-phase extraction columns and injected onto an HPLC system by the automatic sample preparation with extraction columns (ASPEC) automate. A Superlosil LC-18 (5 microns) column was used for chromatography. The mobile phase was a mixture of an aqueous solution of potassium dihydrogen phosphate, acetonitrile and methanol for the assay in plasma, and of an aqueous solution of tetrabutylammonium hydrogen sulfate, tripotassium phosphate and phosphoric acid and of acetonitrile for the assay in urine. The compounds were detected at 230 nm. The limit of quantitation was 0.11 mumol/l (25 ng/ml) for the assay of CGP 33,101 in plasma, 11 mumol/l (2.5 micrograms/ml) for its assay in urine and 21 mumol/l (5 micrograms/ml) for the assay of CGP 47,292 in urine.
Rouan
M C
MC
Laboratories Ciba-Geigy, Centre de Bioanalyse et Pharmacocinétique, Rueil-Malmaison, France.
Souppart
C
C
Alif
L
L
Moes
D
D
Lecaillon
J B
JB
Godbillon
J
J
D000927:Anticonvulsants / Q000097:blood; D001322:Autoanalysis / Q000379:methods*; D002851:Chromatography, High Pressure Liquid / Q000379:methods* / Q000706:statistics & numerical data; D004827:Epilepsy / Q000097:blood / Q000188:drug therapy; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008832:Microchemistry; D011786:Quality Control; D012680:Sensitivity and Specificity; D012995:Solubility; D014230:Triazoles / Q000032:analysis* / Q000097:blood / Q000652:urine
D000927:Anticonvulsants; D014230:Triazoles; C095532:CGP 47292; C079703:rufinamide